Immunomedics (NASDAQ:IMMU) was upgraded by stock analysts at TheStreet from a “d” rating to a “c-” rating in a research note issued to investors on Friday, February 9th.
Several other equities analysts have also recently issued reports on the stock. Jefferies Group upped their price target on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. BidaskClub upgraded shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research cut shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $19.00.
Shares of Immunomedics (NASDAQ IMMU) traded up $0.38 during trading hours on Friday, reaching $16.47. 1,693,900 shares of the company traded hands, compared to its average volume of 2,511,537. The company has a market cap of $2,730.46, a P/E ratio of -8.15 and a beta of 1.50. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.26 and a current ratio of 1.26. Immunomedics has a fifty-two week low of $4.73 and a fifty-two week high of $18.93.
TRADEMARK VIOLATION NOTICE: “Immunomedics (NASDAQ:IMMU) Upgraded at TheStreet” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://stocknewstimes.com/2018/02/20/immunomedics-immu-upgraded-to-c-at-thestreet.html.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.